Madison Square Garden Sports Corp. has become a one-way street for analyst upgrades — and the stock has obliged, climbing 10% over the past month to $366.34 — yet a steady creep higher in short interest over that same period hints that not everyone is convinced the rally has further to run.
The analyst community has been uniformly constructive. Every firm that touched price targets over the past two weeks has moved them higher. Seaport Global lifted its target to $435 just this week, maintaining Buy. Guggenheim raised to $422 from $401 on May 15, also keeping Buy. Susquehanna moved to $404 from $388. The sole holdout is Citigroup, which sits at Neutral with a $360 target — essentially flat to the current price. The mean target across the street is $386, a modest 5% above the close. That gap is narrow enough to suggest the stock has closed in on consensus expectations faster than analysts have repriced them upward.
The bear case centres on the tax code headwinds and execution risk tied to the potential separation of the Knicks and Rangers into standalone entities. Bulls counter that exactly such a spin-off could unlock substantial embedded value — the franchise assets themselves are widely regarded as underappreciated on the current consolidated balance sheet. Valuation multiples are hard to read cleanly here: the PE is deeply negative and the EV/EBITDA of roughly 547x reflects a business carrying the carrying value of trophy assets rather than earnings power. Factor scores add some nuance: EPS momentum is near the top of the universe — 99th percentile on the 30-day reading — while EPS surprise ranks at just the 9th percentile, meaning the earnings trajectory is improving but actual results have consistently underwhelmed relative to expectations.
Short positioning has been creeping higher and is worth watching. Short interest has risen from around 5.4% of free float in mid-April to 5.9% now — a measured but consistent build over six weeks, not a spike. The borrow market, however, sends no distress signals. Availability is wide at roughly 966% of short interest, meaning there are nearly ten shares available to borrow for every one currently lent out. That figure has actually tightened from above 1,000% at the start of May but remains comfortably in normal territory. Cost to borrow has eased — it fell nearly 12% over the past week to 0.47% annualised, historically low and consistent with a stock that shorts find easy to access. The ORTEX short score of 45 sits in the lower half of its range, and the short score rank places MSGS in the 30th percentile — not a heavily squeezed name.
Options positioning adds a gentle supportive tilt. The put/call ratio is running at 0.64, fractionally below its 20-day average of 0.66 and statistically unremarkable with a z-score near zero. The 52-week low PCR was 0.38 and the high was 2.69 — the current level reads as balanced, with no unusual defensive hedging. After the most recent earnings print on May 8, the stock rose 3.5% on the day and added nearly 6% over the following week — a useful data point given the next event is pencilled in for August 12.
Ownership structure is one of the more distinctive features of the name. The Dolan family trust holds just over 19% of shares, with James Dolan personally owning an additional 1%. The family recently trimmed modestly — Charles Dolan sold just under 5,700 shares across several transactions in February — but the controlling stake remains firmly in place. Silver Lake holds 7.9% and has been flat, while T. Rowe Price added roughly 40,000 shares in Q1 to bring its stake to 5.7%. The Bill & Melinda Gates Foundation holds 2.5%. Institutional ownership is concentrated and generally sticky, which historically limits the free float available for active short-sellers to work with.
What to watch next is the pace of the short interest build heading into summer. If the stock continues to outrun the analyst consensus target — currently just 5% above the close — the Street will face pressure to re-rate again or trim conviction, and the August 12 earnings date becomes the natural next test for whether the fundamental story is catching up with the valuation.
See the live data behind this article on ORTEX.
Open MSGS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
